Astrazeneca Plc (NYSE:AZN – Free Report) – Equities research analysts at Erste Group Bank boosted their FY2026 earnings estimates for Astrazeneca in a note issued to investors on Tuesday, September 8th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings of $10.17 per share for the year, up from their prior forecast of $10.14. The consensus estimate for Astrazeneca’s current full-year earnings is $9.34 per share. Erste Group Bank also issued estimates for Astrazeneca’s FY2027 earnings at $11.44 EPS.
AZN has been the subject of several other reports. CICC Research began coverage on Astrazeneca in a research report on Sunday, August 23rd. They issued an “outperform” rating and a $198.00 price objective for the company. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 30th. The Goldman Sachs Group reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Finally, HSBC downgraded shares of Astrazeneca from a “buy” rating to a “hold” rating in a report on Monday, July 13th. Fourteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Astrazeneca has a consensus rating of “Moderate Buy” and a consensus target price of $206.67.
Astrazeneca Price Performance
NYSE:AZN opened at $163.75 on Monday. The stock has a market capitalization of $253.97 billion, a PE ratio of 24.48, a price-to-earnings-growth ratio of 1.36 and a beta of 0.25. Astrazeneca has a 52 week low of $145.79 and a 52 week high of $212.71. The company has a quick ratio of 0.67, a current ratio of 0.89 and a debt-to-equity ratio of 0.47. The stock’s 50-day moving average price is $165.58 and its 200-day moving average price is $181.86.
Astrazeneca (NYSE:AZN – Get Free Report) last issued its quarterly earnings results on Monday, July 27th. The company reported $2.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.13. The company had revenue of $15.38 billion for the quarter, compared to the consensus estimate of $15.44 billion. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.The firm’s revenue was up 6.4% compared to the same quarter last year. During the same period last year, the business posted $2.17 earnings per share.
Institutional Trading of Astrazeneca
A number of large investors have recently added to or reduced their stakes in the business. Mascoma Wealth Management LLC acquired a new position in Astrazeneca in the first quarter worth about $26,000. MV Capital Management Inc. purchased a new position in shares of Astrazeneca during the 4th quarter valued at $26,000. Roxbury Financial LLC acquired a new position in Astrazeneca during the second quarter worth $29,000. Reflection Asset Management acquired a new position in Astrazeneca in the 4th quarter valued at $31,000. Finally, Resources Management Corp CT ADV bought a new position in Astrazeneca in the 1st quarter worth approximately $35,000. 20.35% of the stock is currently owned by institutional investors.
Key Stories Impacting Astrazeneca
Here are the key news stories impacting Astrazeneca this week:
- Positive Sentiment: Eight-year follow-up from the Phase 3 ADAURA trial showed that adjuvant Tagrisso reduced the risk of death by 47% in the primary patient population and 48% across the overall group with early-stage EGFR-mutated lung cancer. The durable survival benefit supports Tagrisso’s position in AstraZeneca’s oncology portfolio and may strengthen expectations for continued sales. AstraZeneca’s TAGRISSO Achieves 8-Year Survival Milestone
- Positive Sentiment: Analyst earnings estimates for fiscal 2026 were reportedly raised, indicating improved expectations for AstraZeneca’s future profitability. FY2026 EPS Estimates for AstraZeneca Increased
- Neutral Sentiment: Separate coverage highlighted mixed oncology results: strong long-term survival outcomes in lung cancer were accompanied by weaker data in advanced breast cancer, leaving the overall clinical readout uneven. Why Is AstraZeneca Stock Trading Higher Today?
- Negative Sentiment: Etcamah failed to significantly improve progression-free survival in the Phase 3 SERENA-4 trial for first-line advanced breast cancer. Although the result does not affect its existing approved use, it limits the drug’s potential expansion and creates a setback for AstraZeneca’s breast-cancer pipeline. AZN’s Etcamah Fails Late-Stage Study
Astrazeneca Company Profile
AstraZeneca plc is a global biopharmaceutical company focused on the discovery, development and commercialization of prescription medicines. Its principal therapeutic areas include oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology conditions, and rare diseases.
The company’s portfolio includes medicines such as Tagrisso, Imfinzi and Lynparza for cancer; Farxiga for cardiovascular, kidney and metabolic conditions; Fasenra for severe asthma; and Symbicort for respiratory disease.
Featured Stories
- Five stocks we like better than Astrazeneca
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
